685 related articles for article (PubMed ID: 21528473)
21. Insulin-like factor 3 -- a new hormone related to polycystic ovary syndrome?
Szydlarska D; Grzesiuk W; Trybuch A; Kondracka A; Kowalik I; Bar-Andziak E
Endokrynol Pol; 2012; 63(5):356-61. PubMed ID: 23115068
[TBL] [Abstract][Full Text] [Related]
22. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome.
Yildiz BO; Yarali H; Oguz H; Bayraktar M
J Clin Endocrinol Metab; 2003 May; 88(5):2031-6. PubMed ID: 12727950
[TBL] [Abstract][Full Text] [Related]
23. Regulation of gonadotropin secretion: implications for polycystic ovary syndrome.
McCartney CR; Eagleson CA; Marshall JC
Semin Reprod Med; 2002 Nov; 20(4):317-26. PubMed ID: 12536355
[TBL] [Abstract][Full Text] [Related]
24. Muting of androgen negative feedback unveils impoverished gonadotropin-releasing hormone/luteinizing hormone secretory reactivity in healthy older men.
Veldhuis JD; Zwart A; Mulligan T; Iranmanesh A
J Clin Endocrinol Metab; 2001 Feb; 86(2):529-35. PubMed ID: 11158004
[TBL] [Abstract][Full Text] [Related]
25. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
26. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome.
Taylor AE; McCourt B; Martin KA; Anderson EJ; Adams JM; Schoenfeld D; Hall JE
J Clin Endocrinol Metab; 1997 Jul; 82(7):2248-56. PubMed ID: 9215302
[TBL] [Abstract][Full Text] [Related]
27. [Effect of luteinizing hormone vs follicular stimulating hormone ratio on anti-Müllerian hormone secretion and folliculogenesis in patients with polycystic ovarian syndrome].
Li Y; Wei LN; Xiong YL; Liang XY
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):567-70. PubMed ID: 21029609
[TBL] [Abstract][Full Text] [Related]
28. [LH-FSH ratio and Polycystic Ovary Syndrome: A forgotten test?].
Saucedo de la Llata E; Moraga-Sánchez MR; Romeu-Sarrió A; Carmona-Ruiz IO
Ginecol Obstet Mex; 2016 Feb; 84(2):84-94. PubMed ID: 27290835
[TBL] [Abstract][Full Text] [Related]
29. Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome.
Fulghesu AM; Cucinelli F; Pavone V; Murgia F; Guido M; Caruso A; Mancuso S; Lanzone A
Hum Reprod; 1999 Mar; 14(3):611-7. PubMed ID: 10221684
[TBL] [Abstract][Full Text] [Related]
30. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome.
Eldar-Geva T; Spitz IM; Groome NP; Margalioth EJ; Homburg R
Hum Reprod; 2001 Dec; 16(12):2552-6. PubMed ID: 11726573
[TBL] [Abstract][Full Text] [Related]
31. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
32. Evidence for gonadotrophin secretory and steroidogenic abnormalities in brothers of women with polycystic ovary syndrome.
Liu DM; Torchen LC; Sung Y; Paparodis R; Legro RS; Grebe SK; Singh RJ; Taylor RL; Dunaif A
Hum Reprod; 2014 Dec; 29(12):2764-72. PubMed ID: 25336708
[TBL] [Abstract][Full Text] [Related]
33. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
34. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
36. [Interrelationship of abnormal family history in the first degree relatives and clinical phenotype of patients with polycystic ovary syndrome].
Wang Y; Mao WW; Chen YJ; Li MZ; Qiao J; Wang LN
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):756-60. PubMed ID: 18307903
[TBL] [Abstract][Full Text] [Related]
37. The role of plasma renin activity in distinguishing patients with polycystic ovary syndrome (PCOS) from oligomenorrheic patients without PCOS.
Uncu G; Sözer MC; Develioğlu O; Cengiz C
Gynecol Endocrinol; 2002 Dec; 16(6):447-52. PubMed ID: 12626031
[TBL] [Abstract][Full Text] [Related]
38. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
[TBL] [Abstract][Full Text] [Related]
39. Adrenal androgenic response to 2-hour ACTH stimulation test in women with PCOS.
Erel CT; Senturk LM; Oral E; Colgar U; Ertungealp E
Gynecol Endocrinol; 1998 Aug; 12(4):223-9. PubMed ID: 9798131
[TBL] [Abstract][Full Text] [Related]
40. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
van der Westhuizen S; van der Spuy ZM
Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
